HNL Lab Medicine Launches Digital Pathology Program

ALLENTOWN, Pa., July 9, 2024 /PRNewswire/ — HNL Lab Medicine is excited to announce the integration of advanced digital pathology services into its diagnostic offerings, marking a significant milestone in the evolution of patient care and diagnostic precision. This cutting-edge technology is set to revolutionize the way pathological analyses are conducted, providing faster, more accurate results to healthcare providers and their patients.

HNL Lab Medicine continues to set the standard for excellence in laboratory medicine

Digital pathology leverages high-resolution scanning of pathology slides, enabling pathologists to analyze and share detailed digital images instead of traditional glass slides. This transition not only enhances diagnostic accuracy but also facilitates collaboration among specialists, irrespective of their geographical locations. The digital platform allows for more efficient workflows, leading to quicker turnaround times and better patient outcomes.

“With the launch of our digital pathology program, HNL Lab Medicine is leading the way in modern diagnostic services. We have embraced advanced technology to enhance our capabilities far beyond what many other laboratories offer,” stated Dr. Jordan Olson, Chief Medical Officer and Chair of Pathology.

“The adoption of digital pathology at HNL is truly revolutionary. This will enable us to be the best pathologists we can possibly be and most importantly provide the best care for our patients,” stated Dr. Sajjad Malik, Medical Director of Digital Pathology.

By adopting digital pathology, HNL Lab Medicine aims to provide unparalleled diagnostic services that support personalized medicine and innovative treatment strategies. This integration underscores the lab’s commitment to harnessing the latest technological advancements to improve healthcare delivery. The new system enhances the ability to handle complex cases, reduces the risk of errors, and streamlines the diagnostic process, ultimately benefiting patients and healthcare providers alike.

With this launch, HNL Lab Medicine continues to set the standard for excellence in laboratory medicine, ensuring that patients receive the highest quality care driven by the latest advancements in medical technology.

About HNL Lab Medicine

HNL Lab Medicine is a leading multi‐regional, full‐service medical laboratory providing testing and related services to physician offices, hospitals, long‐term care facilities, employers and industrial accounts. With 50+ patient service centers in Pennsylvania and 14 acute care laboratories within partners’ hospital sites, and over 40 board-certified pathologists and scientific directors, HNL Lab Medicine provides high-quality, advanced diagnostic testing. Learn more at HNL.com.

Media Contact: Alexandra Ford
alexandra.ford@hnl.com
484-425-8007

View original content to download multimedia:https://www.prnewswire.com/news-releases/hnl-lab-medicine-launches-digital-pathology-program-302192637.html

SOURCE HNL Lab Medicine

Staff

Recent Posts

AI-Era Position Statement to Protect the Integrity of Healthcare, Technology, and Services Benchmarking published by Black Book Research

Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…

22 hours ago

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…

22 hours ago

Embers to Empowerment: The Womb Room Reopens in Govans, Expanding Community-Centered Perinatal Care After Hampden Fire

Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…

22 hours ago

Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles

Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…

22 hours ago

Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase Merger

CRANFORD, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or…

22 hours ago

Park Dental Partners Announces Dates for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK), a leading…

22 hours ago